Market Cap 46.42M
Revenue (ttm) 4.01M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -672.57%
Debt to Equity Ratio 0.00
Volume 604,739
Avg Vol 7,024,410
Day's Range N/A - N/A
Shares Out 15.12M
Stochastic %K 56%
Beta -0.63
Analysts Strong Sell
Price Target $18.71

Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
walker7782
walker7782 Aug. 14 at 7:13 PM
$CRVO Scaling back in starting 2.74
0 · Reply
Doki0926
Doki0926 Aug. 14 at 6:39 PM
$CRVO szemét geci itt mindenki! A biztos bukásban hisztek szarházi mocskok!
0 · Reply
Doki0926
Doki0926 Aug. 14 at 6:39 PM
$CRVO kurva anyátok!!!
0 · Reply
Stu_padasso
Stu_padasso Aug. 14 at 4:27 PM
$CRVO lets drop some good news ah today and eff shorts 🤓
1 · Reply
MV0527
MV0527 Aug. 14 at 11:02 AM
$CRVO waiting game.
1 · Reply
ibaian
ibaian Aug. 14 at 2:01 AM
$CRVO 5 x possible on support news, I remember RANI went 10 x on milestone payments
0 · Reply
Spindr88
Spindr88 Aug. 13 at 4:17 PM
$CRVO I would give my left nut to get out of this… maybe not but cmon… all of these 18-25 targets and can barely hold 3, analysts seem to have gotten the analysis wrong. Isn’t that their job?
1 · Reply
Stu_padasso
Stu_padasso Aug. 13 at 3:32 PM
$CRVO back to 2.5 bummer oh well
0 · Reply
elbardinnyo
elbardinnyo Aug. 13 at 3:29 PM
$CRVO this is a shit
0 · Reply
generaltom
generaltom Aug. 13 at 9:31 AM
$CRVO feels to me we are a couple of months away from significant news. Hopefully after October readout the stars will align. While the readout isn’t a huge pivotal study it could provide evidence that neflamapimod can be used in a wider context than just DLB making any partnership terms more favourable to Cervomed and its shareholders. Who knows what the price does before then.
2 · Reply
Latest News on CRVO
CervoMed price target lowered to $18 from $27 at Canaccord

2026-08-10T11:05:44.000Z - 4 days ago

CervoMed price target lowered to $18 from $27 at Canaccord


CervoMed Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 7 days ago

CervoMed Quarterly report: Q2 2026


CervoMed Earnings release: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 7 days ago

CervoMed Earnings release: Q2 2026


CervoMed completes enrollment in neflamapimod study

2026-07-09T11:40:46.000Z - 5 weeks ago

CervoMed completes enrollment in neflamapimod study


CervoMed Registration statement: Registration filing

Jul 6, 2026, 8:00 AM EDT - 5 weeks ago

CervoMed Registration statement: Registration filing


CervoMed announces $10.5M private placement

2026-06-10T11:44:51.000Z - 2 months ago

CervoMed announces $10.5M private placement


CervoMed announces $10.5M private placement

2026-06-10T11:41:14.000Z - 2 months ago

CervoMed announces $10.5M private placement


CervoMed Slides: Corporate presentation

Jun 10, 2026, 7:00 AM EDT - 2 months ago

CervoMed Slides: Corporate presentation


CervoMed price target lowered to $9 from $11 at Roth Capital

2026-05-18T21:35:08.000Z - 3 months ago

CervoMed price target lowered to $9 from $11 at Roth Capital


CervoMed Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

CervoMed Quarterly report: Q1 2026


CervoMed Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

CervoMed Earnings release: Q1 2026


CervoMed Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

CervoMed Proxy statement: Proxy filing


CervoMed presents neflamapimod MRI data

2026-04-22T14:32:59.000Z - 4 months ago

CervoMed presents neflamapimod MRI data


CervoMed Transcript: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 5 months ago

CervoMed Transcript: The 38th Annual Roth Conference


CervoMed Slides: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 5 months ago

CervoMed Slides: The 38th Annual Roth Conference


CervoMed’s neflamapimod shows efficacy in dementia with DLB

2026-03-19T11:56:17.000Z - 5 months ago

CervoMed’s neflamapimod shows efficacy in dementia with DLB


CervoMed price target lowered to $11 from $19 at Roth Capital

2026-03-17T23:00:26.000Z - 5 months ago

CervoMed price target lowered to $11 from $19 at Roth Capital


CervoMed price target raised to $21 from $15 at Chardan

2026-03-17T22:25:46.000Z - 5 months ago

CervoMed price target raised to $21 from $15 at Chardan


CervoMed Earnings release: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 5 months ago

CervoMed Earnings release: Q4 2025


CervoMed Annual report: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 5 months ago

CervoMed Annual report: Q4 2025


CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

2026-03-17T11:46:53.000Z - 5 months ago

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024


CervoMed Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

CervoMed Slides: Corporate presentation


CervoMed completes Phase 1 volunteer study for neflamapimod

2026-03-04T12:41:24.000Z - 5 months ago

CervoMed completes Phase 1 volunteer study for neflamapimod


CervoMed initiated with an Overweight at Cantor Fitzgerald

2025-12-18T11:40:57.000Z - 8 months ago

CervoMed initiated with an Overweight at Cantor Fitzgerald


CervoMed’s neflamapimod shows efficacy in slowing dementia

2025-12-04T22:05:45.000Z - 9 months ago

CervoMed’s neflamapimod shows efficacy in slowing dementia


CervoMed Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

CervoMed Earnings release: Q3 2025


CervoMed Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

CervoMed Quarterly report: Q3 2025


CervoMed Transcript: Emerging Growth Conference

Oct 22, 2025, 11:25 AM EDT - 10 months ago

CervoMed Transcript: Emerging Growth Conference


CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 10 months ago

CervoMed to Present at the Emerging Growth Conference


CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 1 year ago

CervoMed to Participate in Upcoming Investor Conferences


CervoMed Earnings release: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q2 2025


CervoMed Quarterly report: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

CervoMed Quarterly report: Q2 2025


CervoMed Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Transcript: Status Update


CervoMed Press release: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Press release: Status Update


CervoMed Slides: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Status Update


CervoMed Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation


CervoMed Slides: Corporate Presentation

May 28, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation


CervoMed Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Earnings release: Q1 2025


CervoMed Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Quarterly report: Q1 2025


CervoMed Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

CervoMed Proxy statement: Proxy Filing


CervoMed Slides: Investor Presentation

Apr 5, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed Earnings release: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q4 2024


CervoMed Annual report: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Annual report: Q4 2024


CervoMed Slides: Investor Presentation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed Slides: Investor Presentation

Jan 31, 2025, 7:00 AM EST - 1 year ago

CervoMed Slides: Investor Presentation


CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals


CervoMed Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 3:00 PM EST - 1 year ago

CervoMed Transcript: Stifel 2024 Healthcare Conference


CervoMed Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Quarterly report: Q3 2024


CervoMed Registration statement: Registration Filing

Oct 3, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing


CervoMed Quarterly report: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q2 2024


CervoMed Earnings release: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Earnings release: Q2 2024


CervoMed Transcript: Status Update

Jul 23, 2024, 10:00 AM EDT - 2 years ago

CervoMed Transcript: Status Update


CervoMed Slides: Corporate Presentation

Jul 22, 2024, 8:00 AM EDT - 2 years ago

CervoMed Slides: Corporate Presentation


CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in the Emerging Growth Conference


CervoMed Registration statement: Registration Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing


CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Appoint William Elder as Chief Financial Officer


CervoMed Quarterly report: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q1 2024


CervoMed Earnings release: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Earnings release: Q1 2024


CervoMed Registration statement: Registration Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing


CervoMed Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

CervoMed Proxy statement: Proxy Filing


walker7782
walker7782 Aug. 14 at 7:13 PM
$CRVO Scaling back in starting 2.74
0 · Reply
Doki0926
Doki0926 Aug. 14 at 6:39 PM
$CRVO szemét geci itt mindenki! A biztos bukásban hisztek szarházi mocskok!
0 · Reply
Doki0926
Doki0926 Aug. 14 at 6:39 PM
$CRVO kurva anyátok!!!
0 · Reply
Stu_padasso
Stu_padasso Aug. 14 at 4:27 PM
$CRVO lets drop some good news ah today and eff shorts 🤓
1 · Reply
MV0527
MV0527 Aug. 14 at 11:02 AM
$CRVO waiting game.
1 · Reply
ibaian
ibaian Aug. 14 at 2:01 AM
$CRVO 5 x possible on support news, I remember RANI went 10 x on milestone payments
0 · Reply
Spindr88
Spindr88 Aug. 13 at 4:17 PM
$CRVO I would give my left nut to get out of this… maybe not but cmon… all of these 18-25 targets and can barely hold 3, analysts seem to have gotten the analysis wrong. Isn’t that their job?
1 · Reply
Stu_padasso
Stu_padasso Aug. 13 at 3:32 PM
$CRVO back to 2.5 bummer oh well
0 · Reply
elbardinnyo
elbardinnyo Aug. 13 at 3:29 PM
$CRVO this is a shit
0 · Reply
generaltom
generaltom Aug. 13 at 9:31 AM
$CRVO feels to me we are a couple of months away from significant news. Hopefully after October readout the stars will align. While the readout isn’t a huge pivotal study it could provide evidence that neflamapimod can be used in a wider context than just DLB making any partnership terms more favourable to Cervomed and its shareholders. Who knows what the price does before then.
2 · Reply
BPler
BPler Aug. 13 at 6:36 AM
$CRVO https://youtu.be/1ofXEDCmpkA?is=zH0iqMLjANis6GON
1 · Reply
BPler
BPler Aug. 13 at 6:27 AM
$CRVO https://www.tipranks.com/news/ratings/cervomed-buy-rating-reiterated-as-dementia-pipeline-advances-25-price-target-maintained-ratings-news
0 · Reply
MV0527
MV0527 Aug. 12 at 7:51 PM
$CRVO To the moon.
2 · Reply
Doki0926
Doki0926 Aug. 12 at 7:12 PM
$CRVO 🤣🤣🤣🤣🤣🤣
0 · Reply
elbardinnyo
elbardinnyo Aug. 12 at 2:51 PM
$CRVO vertex partnership!!!
4 · Reply
5layer
5layer Aug. 12 at 12:20 PM
$CRVO very
0 · Reply
SteveO_TX_to_FL
SteveO_TX_to_FL Aug. 12 at 12:34 AM
$CRVO I watched the fireside chat. Dr. Alam confirmed they are seeking one, or more, partnerships for Phase 3. He also gave a compelling backstory on the DLB community’s (very) recent publications, and how that confirms the mechanism of action. Not just alleviating symptoms, but actually reversing the disease progress in some instances. They aren’t going to sign a partnership based on a made-up calendar schedule, but instead are weighing options from the very different types of proposals. It’s happening, I just can’t tell you when.
2 · Reply
DrNeega
DrNeega Aug. 11 at 9:54 PM
$CRVO lol surprised it stayed up
1 · Reply
elbardinnyo
elbardinnyo Aug. 11 at 8:50 PM
$CRVO shitmed
0 · Reply
elbardinnyo
elbardinnyo Aug. 11 at 7:14 PM
$CRVO this is a shit running to 2.5
1 · Reply
bhkk
bhkk Aug. 11 at 6:57 PM
$CRVO $MDCX AH runner ..loading zone
0 · Reply
Pineapple567
Pineapple567 Aug. 11 at 6:38 PM
$CRVO will finance phase 3 themselves👀
2 · Reply